Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

REAL3 Trial of Efficacy of EOX With/Without Panitumumab in Previously Untreated Adv OG Cancer

This study has been terminated.
(Lack of efficacy)
Information provided by (Responsible Party):
Professor David Cunningham, Royal Marsden NHS Foundation Trust Identifier:
First received: January 16, 2009
Last updated: December 10, 2012
Last verified: December 2012